Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

Launched by FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO CARLO BESTA · Feb 26, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on improving the diagnosis and treatment of conditions like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Currently, diagnosing these diseases mainly depends on the symptoms patients show, which can make it tricky. The goal of the study is to find new biological markers, or "fingerprints," that could help doctors identify these conditions more accurately and track how they progress over time. Researchers will use advanced techniques to analyze tissue samples and look for specific proteins and genetic information that could provide insights into these diseases.

To participate in this trial, individuals aged 65 to 74 who have been diagnosed with ALS or FTD may be eligible. There are no specific exclusions listed, which means a wide range of patients can potentially take part. Participants can expect to contribute to groundbreaking research that aims to lead to better diagnostic tools and treatments for these challenging diseases. It's an exciting opportunity to help advance our understanding of ALS and FTD while potentially benefiting future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical criteria for ALS (Brooks et al., 2000; de Carvalho M., 2008), FTD (GornoTempini et al., 2011; Rascovsky et al., 2011)
• Exclusion Criteria:
• • na